Comparison
Ipamorelin vs. Octreotide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Research other
CAS no.
170851-70-4
83150-76-9
Molecular weight
711.86 g/mol
1019.24 g/mol
Half-life
2 h
1.7 h
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Mechanism of action
Ipamorelin
Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
3
4
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
2